Multiplikator forward rega marang pendapatan: Imunon (IMNN)
Imunon, Inc. (IMNN) develops DNA vaccines to combat oncology, leveraging the success of medical trials. The absence of current sales makes the stock price dependent on research, which is illustrated by the forward P/S based on forecasts on the general GURU.Markets platform chart, where the value of 127.20 characterizes this level. The strategy is based on the TheraPlas system for patients with severe forms of tumors.
imunon.com - rincian analitis lan metrik utama (IMNN)
- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi bursa perusahaan:
- rincian valuasi buku bisnis:
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas Imunon, Inc.|IMNN - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Imunon|IMNN - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku IMNN|IMNN - Tanggungan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Imunon|Rasio cepet imunon.com
- rincian asil keuangan lan kelipatan valuasi:
IMNN - Bathi resik|Proyeksi bathi mangsa ngarep Imunon, Inc.|IMNN - Periode bali modal bisnis|Rega marang bathi mangsa ngarep Imunon|IMNN - Pangali rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan IMNN|IMNN - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan Imunon|IMNN - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan imunon.com|IMNN - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Imunon, Inc.
- indikator volume dodolan lan pendapatan:
Pambiji fundamental perusahaan:Celsion Corporation IMNN
Conservative capital requires transparent forecasting of business sustainability, which is why this indicator compares current market capitalization with expected sales volume to assess the company's margin of safety. The forward P/S dynamics for Imunon, Inc. (IMNN) reflect market expectations regarding the commercialization of DNA plasmid therapy for ovarian cancer, allowing investors to evaluate the extent to which R&D risks are currently priced into the stock.
Analisis pesaing Imunon, Inc.
Multiplikator Forward P/S TEM (Tempus AI, Inc.)|QGEN - Multiplikator forward rega marang pendapatan|IONS: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Repligen Inc. RGEN|RNA: Multiplikator Forward P/S|CRSP - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan GeneDx|Multiplikator forward rega marang pendapatan Ultragenyx Pharmaceutical Inc. (RARE)|Rasio rega marang prakiraan pendapatan Beam Therapeutics Corp (BEAM)|Sarepta Corp - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Twist Bioscience TWST|TXG: Kapitalisasi marang prakiraan pendapatan|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|STOK (Stoke Therapeutics Inc) - Kapitalisasi marang prakiraan pendapatan|BioLife Corp (BLFS) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan WVE|MAZE (Maze Therapeutics Inc) - Multiplikator Forward P/S|Multiplikator Forward P/S sionnatx.com|Multiplikator Forward P/S PRME|Rasio kapitalisasi marang dodolan sing dikarepake Taysha Gene Therapies Inc|Rasio rega marang prakiraan pendapatan uniQure Corp QURE|MGTX - Multiplikator forward rega marang pendapatan|RGNX: Multiplikator forward rega marang pendapatan|SLDB - Multiplikator Forward P/S|Ocugen (OCGN) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan PACB|Rasio rega marang prakiraan pendapatan Benitec|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Design Corp DSGN|Rasio rega marang prakiraan pendapatan Rocket Pharmaceuticals (RCKT)|4dmoleculartherapeutics.com - Kapitalisasi marang prakiraan pendapatan|Lexeo Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan KRRO|Editas - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Silence Therapeutics Corp SLN|proqr.com (PRQR) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan CDXS|SGMO (Sangamo Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Nautilus Biotechnology Inc (NAUT)|Multiplikator forward rega marang pendapatan MGX (Metagenomi, Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Precision BioSciences Inc.|Multiplikator Forward P/S GBIO (Generation Bio)|Rasio kapitalisasi marang dodolan sing dikarepake boundlessbio.com (BOLD)|XCUR - Rasio rega marang prakiraan pendapatan|Phio Pharmaceuticals (PHIO) - Multiplikator forward rega marang pendapatan|mustangbio.com (MBIO) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan RNAZ|Rasio rega marang prakiraan pendapatan Bionano Genomics Inc.|Kapitalisasi marang prakiraan pendapatan APDN (adnas.com)|Multiplikator Forward P/S BLUE|immunoprecise.com - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|Regulus Therapeutics - Multiplikator Forward P/S|SYRS - Multiplikator Forward P/S|TBIO: Multiplikator Forward P/S|TCON - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Unity Bio
